Authors
Dimitrios Kalogeropoulos, Paul Barach, Andrea Downing, Stefaan Verhulst, Maryam Lustberg
Published in
Cancer medicine. Volume 15. Issue 10. Pages e72371.
Abstract
Healthcare services and data ecosystems remain fragmented, inequitable and misaligned with patient, clinician and public health needs. Three pathways to patient-centred Artificial Intelligence (AI) have emerged to address this: data collaboration, Whole System Approaches and digital inclusion. Each has advanced the field. However, none delivers the continuous, participatory and outcome-grounded learning that equitable AI demands. The populations whose data drives AI learning must also be the populations who benefit from it. This principle has not been structurally embedded in any existing pathway. This narrative review defines a framework for operationalising Adaptive Machine Learning (AML) as a fourth, integrative pathway to patient-centred AI. AML is defined as continuous learning from real-world individual-level data to generate personalised, population-level insights returning direct benefit to the communities who produce them. A narrative review of PubMed and Google Scholar (2018-2025) was conducted across five thematic domains: AI and machine learning in healthcare; real-world data and evidence; patient-centred care and digital health; data governance and AI regulation; and adaptive clinical trial design. Search terms covered healthcare AI applications and adaptive, continuously learning systems, emphasising prediction-oriented rather than static diagnostic approaches. Eligibility was determined through iterative thematic analysis. Eight systemic barriers to patient-centred AI are identified and the three existing pathways critically examined for limitations in addressing bias, validation and equitable implementation. AML is proposed as the mechanism that closes this gap, connecting systems medicine, personalised medicine and precision medicine through continuous, outcome-based learning, identifying three original conceptual contributions as enablers: Integrative Data Governance (IDG), Adaptive Clinical Trial (ACT) designs and Evidence Sandbox Facilities (ESFs). Progress requires globally standardised Healthcare Data Recycling frameworks, adaptive evaluation methodologies and ESFs enabling multi-stakeholder validation. Future research should address federated AML validation, collective consent mechanisms and alignment of regulatory frameworks with international AI governance standards.
PMID:
42860029
Bibliographic data and abstract were imported from PubMed on 12 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 10
- Comments 0